Form 4: Acrivon COO Withholds Shares for RSU Taxes

COO Eric Devroe had 613 ACRV shares withheld at $2.24 to cover taxes on RSU vesting, leaving 65,308 shares beneficially owned.

Summary

• On 11/14/2025, Chief Operating Officer Eric Devroe had 613 shares of Acrivon Therapeutics, Inc. common stock withheld by the issuer to satisfy mandatory tax withholding upon RSU vesting (transaction code F).
• The withholding was valued at $2.24 per share.
• Following the transaction, Devroe beneficially owns 65,308 shares, held directly.
• The Form 4 was signed by Adam D. Levy, Attorney-in-Fact, on 11/18/2025.

Sentiment

Score: 5

Explanation: Neutral, routine insider tax-withholding related to RSU vesting with minimal impact on ownership or market signaling.

Positives

• Event reflects tax withholding upon RSU vesting (code F), not an open-market sale, minimizing negative signaling.
• Insider continues to hold 65,308 shares directly, indicating ongoing alignment with shareholders.
• No sales of derivative securities or option exercises were disclosed.

Negatives

• Insider holdings decreased by 613 shares due to tax withholding.
• No accompanying operational or financial performance details are provided in this report.

Future Outlook

No guidance or forward-looking statements are provided; this is an administrative tax-withholding event tied to RSU vesting.

Management Comments

• “Shares withheld by the Issuer to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units.”

Industry Context

Routine RSU tax-withholding entries (code F) are common across biotech and broader life sciences companies that compensate executives with equity; such events generally carry limited signaling about company fundamentals or strategy.

Comparison to Industry Standards

• Consistent with standard executive equity compensation practices in biotech, where RSU vesting triggers issuer share withholding for taxes (code F).
• Similar administrative Form 4 entries are frequently observed at peers such as Moderna (MRNA), Alnylam (ALNY), and Beam Therapeutics (BEAM), typically without open‑market sales.
• The modest size of the withholding and the retention of a meaningful residual position align with typical insider ownership patterns in development‑stage biotech companies.

Stakeholder Impact

• Shareholders: Minimal impact; no open-market sale occurred, and insider maintains 65,308 shares.
• Employees: Confirms ongoing equity compensation and RSU vesting practices.
• Company/treasury: Shares withheld to cover taxes are typically retained by the issuer, an administrative settlement.

Key Dates

Keywords

Acrivon Therapeutics, ACRV, Form 4, insider transaction, beneficial ownership, restricted stock units, RSU vesting, tax withholding, code F, biotech